Optimal Genetic Screening for Cystic Fibrosis

References

• Accurso FJ, Sontag MK, Wagener JS (2005) Complications associated with symptomatic diagnosis in infants with cystic fibrosis. J. Pediatrics 147(3):S37–S41.Crossref, Google Scholar
• Adams WP, Sherali HD (1986) A tight linearization and an algorithm for zero-one quadratic programming problems. Management Sci. 32(10):1274–1290.Link, Google Scholar
• Advisory Committee on Heritable Disorders in Newborns and Children (2018) Recommended uniform screening panel core conditions. Accessed November 2019, https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/heritable-disorders/rusp/rusp-uniform-screening-panel.pdf.Google Scholar
• Aprahamian H, Bish EK, Bish DR (2018) Adaptive risk-based pooling in public health screening. IISE Trans. 50(9):753–766.Crossref, Google Scholar
• Aprahamian H, Bish DR, Bish EK (2019) Optimal risk-based group testing. Management Sci. 65(9):4365–4384.Link, Google Scholar
• Baby’s First Test (2019) Accessed November 2019, http://www.babysfirsttest.org/newborn-screening/states.Google Scholar
• Bell SC, Boeck KD, Amaral MD (2015) New pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls. Pharmacology Therapeutics 145:19–34.Crossref, Google Scholar
• Ben-Tal A, Nemirovski A (2000) Robust solutions of linear programming problems contaminated with uncertain data. Math. Programming 88(3):411–424.Crossref, Google Scholar
• Ben-Tal A, El Ghaoui L, Nemirovski A (2009) Robust Optimization, Princeton Series in Applied Mathematics (Princeton University Press, Princeton, NJ).Crossref, Google Scholar
• Bertsimas D, Sim M (2004) The price of robustness. Oper. Res. 52(1):35–53.Link, Google Scholar
• Bertsimas D, Brown DB, Caramanis C (2011) Theory and applications of robust optimization. Soc. Indust. Appl. Math. 5(1):15–20.Google Scholar
• Bish DR, Bish EK, Xie RS, Stramer SL (2014) Going beyond “same-for-all” testing of infectious agents in donated blood. IIE Trans. 46(11):1147–1168.Google Scholar
• Borowitz D, Parad RB, Sharp JK, Sabadosa KA, Robinson KA, Rock MJ, Farrell PM, et al. (2009) Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. J. Pediatrics155(6):S106–S116.Crossref, Google Scholar
• Boyle MP, Boeck KD (2013) A new era in the treatment of cystic fibrosis: Correction of the underlying CFTR defect. Lancet Respiratory Medicine 1(2):158–163.Crossref, Google Scholar
• California Department of Public Health (2019) Genetic disease screening program. Accessed November 2019, https://www.cdph.ca.gov/Programs/CFH/DGDS/CDPH%20Document%20Library/FY%202019-20%20GDSP%20November%20Estimate%20%201.9.19%20DOF%20Final.pdf.Google Scholar
• Campbell PW, White TB (2005) Newborn screening for cystic fibrosis: An opportunity to improve care and outcomes. J. Pediatrics 147(3):S2–S5.Crossref, Google Scholar
• Capara A, Kellerer H, Pferschy U, Pisinger D (2000) Approximation algorithms for knapsack problems with cardinality constraints. Eur. J. Oper. Res. 123(2):333–345.Crossref, Google Scholar
• Centers for Disease Control and Prevention (2018) Birth data. Accessed September 2020, https://www.cdc.gov/nchs/nvss/births.htm?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fnchs%2Fbirths.htm.Google Scholar
• Chinneck J, Ramadan K (2000) Linear programming with interval coefficients. J. Oper. Res. Soc. 51(2):209–220.Crossref, Google Scholar
• Clinical and Functional Translation of CFTR (2018) Accessed May 2018, https://www.cftr2.org/.Google Scholar
• Cochran AL, Tarini BA, Kleyn M, Zayas-Cabán G (2018) Newborn screening collection and delivery processes in Michigan Birthing Hospitals: Strategies to improve timeliness. Maternal Child Health J. 22(10):1436–1443.Crossref, Google Scholar
• Cunningham J, Taussig L (2013) An Introduction to Cystic Fibrosis for Patients and Their Families, 6th ed. (Cystic Fibrosis Foundation, Bethesda, MD).Google Scholar
• Currier RJ, Sciortino S, Liu R, Bishop T, Koupaei RA, Feuchtbaum L (2017) Genomic sequencing in cystic fibrosis newborn screening: What works best, two-tier predefined CFTR mutation panels or second-tier CFTR panel followed by third-tier sequencing? Genetics Medicine 19(10):1159–1163.Crossref, Google Scholar
• Cystic Fibrosis Foundation (2009) All fifty states to screen newborns for cystic fibrosis by 2010. Accessed May 2018, https://www.cff.org/About-Us/Media-Center/Press-Releases/All-Fifty-States-to-Screen-Newborns-for-Cystic-Fibrosis-by-2010/.Google Scholar
• Cystic Fibrosis Foundation (2017) Sweat test. Accessed November 2019, https://www.cff.org/What-is-CF/Testing/Sweat-Test/.Google Scholar
• Cystic Fibrosis Foundation (2018) 2018 patient registry annual data report. Accessed September 2020, https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2018-Patient-Registry-Annual-Data-Report.pdf.Google Scholar
• Cystic Fibrosis Foundation (2019) Carrier testing for cystic fibrosis. Accessed November 2019, https://www.cff.org/What-is-CF/Testing/Carrier-Testing-for-Cystic-Fibrosis/.Google Scholar
• Deignan JL, Astbury C, Cutting GR, del Gaudio D, Gregg AR, Grody WW, Monaghan KG, Richards S, ACMG Laboratory Quality Assurance Committee (2020) CFTR variant testing: A technical standard of the American College of Medical Genetics and Genomics (ACMG). Genetics Medicine 22(5):1288–1295.Crossref, Google Scholar
• Department of Health Wadsworth Center (2017) Changes to the New York newborn screening program’s cystic fibrosis screening protocol. Accessed December 2019, https://www.wadsworth.org/sites/default/files/WebDoc/26704185/CF%20Algorithm%20Change%20Notification%20Effective%2012-1-17.pdf.Google Scholar
• Devroye L (1986) Non-Uniform Random Variate Generation (Springer-Verlag, New York).Crossref, Google Scholar
• Dorfman R (1943) The detection of defective members of large populations. Ann. Math. Statist. 14(4):436–440.Crossref, Google Scholar
• El Amine H, Bish EK, Bish DR (2018) Robust post-donation blood screening under prevalence rate uncertainty. Oper. Res. 66(1):1–17.Link, Google Scholar
• Farrell PM, Lai HJ, Li Z, Kosorok MR, Laxova A, Green CG (2005) Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: Enough is enough! Pediatrics 147(3):S30–S36.Crossref, Google Scholar
• Food and Drug Administration (2018) Approved drug products. Accessed December 2019, https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/UCM071436.pdf.Google Scholar
• Grosse SD (2015) Showing value in newborn screening: Challenges in quantifying the effectiveness and cost-effectiveness of early detection of phenylketonuria and cystic fibrosis. Health Care (Don Mills) 3(4):1133–1157.Google Scholar
• Grosse SD, Boyle CA, Botkin JR, Comeau AM, Kharrazi M, Rosenfeld M, Wilfond BS (2004) Newborn screening for cystic fibrosis: Evaluation of benefits and risks and recommendations for state newborn screening programs. Morbidity Mortality Weekly Rep. 53(40):1–36.Google Scholar
• Gurobi Optimization (2019) Gurobi optimizer reference manual. Accessed December 2019, https://www.gurobi.com/documentation/9.0/refman/index.html.Google Scholar
• Hughes EE, Stevens CF, Saavedra-Matiz CA, Tavakoli NP, Krein LM, Parker A, Zhang Z, et al. (2015) Clinical sensitivity of cystic fibrosis mutation panels in a diverse population. Human Mutation 37(2):201–208.Crossref, Google Scholar
• Hull SC, Kass NE (2000) Adults with cystic fibrosis and (in) fertility: How has the health care system responded? J. Andrology 21(6):809–813.Google Scholar
• Hwang FK (1975) A generalized binomial group testing problem. J. Amer. Statist. Assoc. 70(352):923–926.Crossref, Google Scholar
• Illumina (2019) MiSeqDx cystic fibrosis clinical sequencing assay. Accessed November 2019, https://www.illumina.com/products/by-type/ivd-products/miseqdx-cystic-fibrosis-clinical-sequencing-assay.html.Google Scholar
• Johns Hopkins Medicine (2019) Cystic fibrosis and CF-related disorders NGS panel. Accessed June 2019, https://www.hopkinsmedicine.org/dnadiagnostic/tests/tests/cystic-fibrosis-and-cf-related-disorders-ngs-panel.Google Scholar
• Johnson MA, Yoshitomi MJ, Richards CS (2007) A comparative study of five technologically diverse CFTR testing platforms. J. Molecular Diagnostics 9(3):401–407.Crossref, Google Scholar
• Jorde LB, Carey JC, Bamshad MJ (2015) Medical Genetics e-Book, 5th ed. (Elsevier Health Sciences, Philadelphia).Google Scholar
• Kammesheidt A, Kharrazi M, Graham S, Young S, Pearl M, Dunlop C, Keiles S (2006) Comprehensive genetic analysis of the cystic fibrosis transmembrane conductance regulator from dried blood specimens—Implications for newborn screening. Genetics Medicine 8(9):557–562.Crossref, Google Scholar
• Kay DM, Maloney B, Hamel R, Pearce M, DeMartino L, McMahon R, McGrath E, et al. (2015) Screening for cystic fibrosis in New York state: Considerations for algorithm improvements. Eur. J. Pediatrics 175(2):181–193.Crossref, Google Scholar
• Kellerer H, Pferschy U, Pisinger D (2004) Knapsack Problems (Springer-Verlag Berlin Heidelberg GmbH, New York).Crossref, Google Scholar
• Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui L (1989) Identification of the cystic fibrosis gene: Genetic analysis. Sci. 245(4922):1073–1080.Crossref, Google Scholar
• Kharrazi M, Yang J, Bishop T, Lessing S, Young S, Graham S, Pearl M, et al. (2015) Newborn screening for cystic fibrosis in California. Pediatrics 136(6):1062–1072.Crossref, Google Scholar
• Kloosterboer M, Hoffman G, Rock M, Gershan W, Laxova A, Li Z, Farrell PM (2009) Clarification of laboratory and clinical variables that influence cystic fibrosis newborn screening with initial analysis of immunoreactive trypsinogen. Pediatrics 123(2):e338–e346.Crossref, Google Scholar
• Kosheleva K, Faulkner N, Robinson K, Umbarger M (2017) Validation of a novel copy number variant detection algorithm for CFTR from targeted next generation sequencing data. Fertility Sterility 108(3):e269.Crossref, Google Scholar
• Lee DS, Rosenberg MA, Peterson A, Makholm L, Hoffman G, Laessig RH, Farrell PM (2003) Analysis of the costs of diagnosing cystic fibrosis with a newborn screening program. J. Pediatrics 142(6):617–623.Crossref, Google Scholar
• Lim RM, Silver AJ, Silver MJ, Borroto C, Spurrier B, Petrossian TC, Larson JL, Silver LM (2016) Targeted mutation screening panels expose systematic population bias in detection of cystic fibrosis risk. Genetics Medicine 18(2):174–179.Crossref, Google Scholar
• Martino L, Luengo D, Míguez J (2018) Accept–reject methods. Independent Random Sampling Methods (Springer International Publishing, Cham, Switzerland), 65–113.Crossref, Google Scholar
• McMahan CS, Tebbs JM, Bilder CR (2012) Informative Dorfman screening. Biometrics 68(1):287–296.Crossref, Google Scholar
• Mehta A (2007) A global perspective on newborn screening for cystic fibrosis. Current Opinion Pulmonary Medicine 13(6):510–514.Crossref, Google Scholar
• National Institutes of Health (2016) The cost of sequencing a human genome. Accessed December 2019, https://www.genome.gov/about-genomics/fact-sheets/Sequencing-Human-Genome-cost.Google Scholar
• National Institutes of Health (2019) CFTR gene. Accessed November 2019, https://ghr.nlm.nih.gov/gene/CFTR#.Google Scholar
• Newcombe RG (1998) Two-sided confidence intervals for the single proportion: Comparison of seven methods. Statist. Medicine 17(8):857–872.Crossref, Google Scholar
• Newcombe RG (2003) Confidence intervals for the mean of a variable taking the values 0, 1 and 2. Statist. Medicine 22(17):2737–2750.Crossref, Google Scholar
• Nobibon FT, Leus R (2014) Complexity results and exact algorithms for robust knapsack problems. J. Optim. Theory Appl. 161(2):533–552.Crossref, Google Scholar
• Nshimyumukiza L, Bois A, Daigneault P, Lands L, Laberge AM, Fournier D, Duplantie J, et al. (2014) Cost effectiveness of newborn screening for cystic fibrosis: A simulation study. J. Cystic Fibrosis 13(3):267–274.Crossref, Google Scholar
• Pagaduan JV, Ali M, Dowlin M, Suo L, Ward T, Ruiz F, Devaraj S (2018) Revisiting sweat chloride test results based on recent guidelines for diagnosis of cystic fibrosis. Practical Laboratory Medicine 10:34–37.Crossref, Google Scholar
• Perakis G, Roels G (2008) Regret in the newsvendor model with partial information. Oper. Res. 56(1):188–203.Link, Google Scholar
• Pisinger D (1998) A fast algorithm for strongly correlated knapsack problems. Discrete Appl. Math. 89(1):197–212.Crossref, Google Scholar
• Rock MJ, Hoffman G, Laessig RH, Kopish GJ, Litsheim TJ, Farrell PM (2005) Newborn screening for cystic fibrosis in Wisconsin: Nine-year experience with routine trypsinogen/DNA testing. J. Pediatrics 147(3):S73–S77.Crossref, Google Scholar
• Rosenberg MA, Farrell PM (2005) Assessing the cost of cystic fibrosis diagnosis and treatment. J. Pediatrics 147(3):S101–S105.Crossref, Google Scholar
• Sadeghzadeh S, Bish EK, Bish DR (2020) Optimal data-driven policies for disease screening under noisy biomarker measurement. IISE Trans. 52(2):166–180.Crossref, Google Scholar
• Savage LJ (1951) The theory of statistical decision. J. Amer. Statist. Assoc. 46(253):55–67.Crossref, Google Scholar
• Schmidt M, Werbrouck A, Verhaeghe N, De Wachter E, Simoens S, Annemans L, Putman K (2019) A model-based economic evaluation of four newborn screening strategies for cystic fibrosis in Flanders, Belgium. Acta Clinica Belgica 75(3):212–220.Crossref, Google Scholar
• Schrijver I, Pique L, Graham S, Pearl M, Cherry A, Kharrazi M (2016) The spectrum of CFTR variants in nonwhite cystic fibrosis patients: Implications for molecular diagnostic testing. J. Molecular Diagnostics 18(1):39–50.Crossref, Google Scholar
• Smith JC, Taskin ZC (2008) A tutorial guide to mixed-integer programming models and solution techniques. Optimization in Medicine and Biology (CRC Press, Boca Raton, FL), 521–548.Google Scholar
• Soleimanian A, Jajaei GS (2013) Robust nonlinear optimization with conic representable uncertainty set. Eur. J. Oper. Res. 228(2):337–344.Crossref, Google Scholar
• Tluczek A, Koscik RL, Farrell PM, Rock MJ (2005) Psychosocial risk associated with newborn screening for cystic fibrosis: Parents’ experience while awaiting the sweat-test appointment. Pediatrics 115(6):1692–1703.Crossref, Google Scholar
• van den Akker ME, Dankert HM, Verkerk PH, Dankert-Roelse JE (2006) Cost-effectiveness of 4 neonatal screening strategies for cystic fibrosis. Pediatrics 118(3):896–905.Crossref, Google Scholar
• van der Ploeg C, van den Akker ME, Vernooij-van Langen A, Elvers L, Gille J, Verkerk P, Dankert-Roelse J, CHOPIN study group (2015) Cost-effectiveness of newborn screening for cystic fibrosis determined with real-life data. J. Cystic Fibrosis 14(2):194–202.Crossref, Google Scholar
• Watson MS, Cutting GR, Desnick RJ, Driscoll DA, Klinger K, Mennuti M, Palomaki GE, et al. (2004) Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genetics Medicine 6(5):387–391.Crossref, Google Scholar
• Wells J, Rosenberg M, Hoffman G, Anstead M, Farrell PM (2012) A decision-tree approach to cost comparison of newborn screening strategies for cystic fibrosis. Pediatrics 129(2):e339–e347.Crossref, Google Scholar
• Willis MS (2012) Multiple positive sweat chloride tests in an infant asymptomatic for cystic fibrosis. Laboratory Medicine 43(2):1–5.Google Scholar
• Yoe C (2019) Principles of Risk Analysis: Decision Making Under Uncertainty (CRC Press, Boca Raton, FL).Crossref, Google Scholar